



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

28 March 2023
EMA/145575/2023
EMA/H/C/005317

Public statement

Dasatinib Accordpharma (dasatinib)

Withdrawal of the marketing authorisation in the European Union

On 25 March 2023, the European Commission withdrew the marketing authorisation for Dasatinib Accordpharma (dasatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Accord Healthcare S.L.U., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Dasatinib Accordpharma was granted marketing authorisation in the EU on 24 March 2022 for the treatment of leukaemia. The product had not been marketed in the EU.

Dasatinib Accordpharma is a generic medicine of Sprycel.

The European Public Assessment Report (EPAR) for Dasatinib Accordpharma will be updated to indicate that the marketing authorisation is no longer valid.

